Back to top
more

PTC Therapeutics (PTCT)

(Delayed Data from NSDQ)

$25.32 USD

25.32
3,910,940

+0.63 (2.55%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $24.92 -0.40 (-1.58%) 5:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for PTCT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for PTC Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 877 411 773 1,104 687
Receivables 161 156 110 70 56
Notes Receivable 0 0 0 0 0
Inventories 31 22 16 19 19
Other Current Assets 150 106 55 39 18
Total Current Assets 1,219 694 954 1,232 779
Net Property & Equipment 87 73 53 34 22
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 462 788 807 798 793
Deposits & Other Assets 36 49 47 61 30
Total Assets 1,896 1,706 1,938 2,208 1,624
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 392 320 289 242 159
Current Portion Long-Term Debt 194 72 209 21 20
Current Portion Capital Leases 3 3 3 1 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 1 1 5 57
Total Current Liabilities 603 406 509 277 236
Mortgages 0 0 0 0 0
Deferred Taxes/Income 56 103 137 137 134
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,904 1,257 957 968 294
Non-Current Capital Leases 17 19 20 23 0
Other Non-Current Liabilities 36 167 240 242 365
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,714 2,053 1,937 1,726 1,029
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,466 2,305 2,124 2,172 1,795
Retained Earnings -3,284 -2,657 -2,098 -1,629 -1,191
Other Equity -1 5 -24 -61 -11
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -819 -347 1 482 594
Total Liabilities & Shareholder's Equity 1,896 1,706 1,938 2,208 1,624
Total Common Equity -819 -347 1 482 594
Shares Outstanding 75.40 72.90 70.70 68.20 61.60
Book Value Per Share -10.86 -4.76 0.02 7.07 9.65

Fiscal Year End for PTC Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 877 295 338 286
Receivables NA 161 166 178 202
Notes Receivable NA 0 0 0 0
Inventories NA 31 36 32 27
Other Current Assets NA 150 44 42 99
Total Current Assets NA 1,219 540 590 613
Net Property & Equipment NA 87 85 82 79
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 462 506 534 769
Deposits & Other Assets NA 36 35 36 48
Total Assets NA 1,896 1,260 1,338 1,609
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 392 371 359 332
Current Portion Long-Term Debt NA 194 106 105 98
Current Portion Capital Leases NA 3 3 2 2
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1 1 0 0
Total Current Liabilities NA 603 492 476 442
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 56 52 52 103
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,904 1,231 1,234 1,238
Non-Current Capital Leases NA 17 17 17 17
Other Non-Current Liabilities NA 39 38 167
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,714 1,931 1,917 2,066
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,466 2,447 2,417 2,340
Retained Earnings NA -3,284 -3,128 -2,995 -2,796
Other Equity NA -1 10 -1 -2
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -819 -671 -579 -458
Total Liabilities & Shareholder's Equity NA 1,896 1,260 1,338 1,609
Total Common Equity 0 -819 -671 -579 -458
Shares Outstanding 76.60 75.40 75.40 74.10 74.10
Book Value Per Share 0.00 -10.86 -8.90 -7.82 -6.17